Paul Herendeen, Elanco’s director, just bought 10,000 shares worth over $236K—boosting his stake to $2.4M—sending a bullish signal as the pet health market rockets toward doubling by 2033. Despite reporting a net loss, Elanco’s $5B revenue surge and strong Q2 results, including a hot-selling dog itch med, fuel investor optimism. His purchase, made at a premium to the day’s close, underscores confidence in Elanco’s growth amid a booming animal health sector.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
